Compara mètodes
Revisa els mètodes seleccionats l'un al costat de l'altre; les files que difereixen es ressalten.
| DLQI infantil (cDLQI)× | Skindex-29 (Skin Disease Quality of Life Instrument)× | |
|---|---|---|
| Camp | Dermatologia | Dermatologia |
| Família | Process / pipeline | Process / pipeline |
| Any d'origen≠ | 1995 | 1997 |
| Autor original≠ | Lewis-Jones MS, Finlay AY | Chren MM, Lasek RJ |
| Tipus≠ | Self-report (parent or child proxy) | Self-report |
| Font seminal≠ | Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949. DOI ↗ | Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. DOI ↗ |
| Àlies | cDLQI, Pediatric DLQI | Skindex, Skindex-QoL |
| Relacionats≠ | 3 | 1 |
| Resum≠ | The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice. | Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes. |
| ScholarGateConjunt de dades ↗ |
|
|